Get the latest Science News and Discoveries

The Lundquist Institute and its start-up company Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID - EurekAlert!

Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.

None

Related news:

An Old Jeweler’s Trick Could Unlock the Next Generation of Nuclear Clocks

Cleveland Clinic presents final results of phase 1 clinical trial of preventive breast cancer vaccine study - EurekAlert!

NIH’s proposed caps on open-access publishing fees roil scientific community